A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

March 31, 2028

Conditions
Primary Immune Thrombocytopenia
Interventions
DRUG

TQB3473 Tablets

TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.

Trial Locations (51)

100020

Beijing Chaoyang Hospital, Capital Medical University, Beijing

100730

Peking Union Medical College Hospital, Beijing

110000

Shenjing Hospital Of China Medical University, Shenyang

130400

The first hospital of Jilin University, Changchun

150001

The First Affiliated Hospital of Harbin Medical University, Harbin

200030

Shanghai Sixth People's Hospital, Shanghai

201700

Affiliated Zhongshan Hospital of Fudan University, Qingpu Branch, Shanghai

210000

Nanjing Drum Tower Hospital, Nanjing

210029

Jiangsu Province Hospital, Nanjing

226006

Affiliated Hospital of Nantong University, Nantong

230001

The first affiliated hospital of ustc anhui provincial hospital, Hefei

241001

The First Affiliated Hospital of Wannan Medical College, Wuhu

250000

Qilu Hospital of Shandong University, Jinan

250013

Shandong First Medical University Affiliated Central Hospital, Jinan

264099

Yantai Yuhuangding Hospital (Affiliated Yantai Yuhuangding Hospital of Qingdao University), Yantai

276401

Linyi Central Hospital, Linyi

300070

Tianjin Medical University General Hospital, Tianjin

300121

Tianjin People's Hospital, Tianjin

310006

Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou

315020

The First Affiliated Hospital of Ningbo University, Ningbo

330006

The First Affiliated Hospital of NanChang University, Nanchang

341001

Ganzhou People's Hospital, Ganzhou

400010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

410035

The Third Hospital of Changsha, Changsha

430000

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Zhongnan Hospital of Wuhan University, Wuhan

450000

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

450003

Henan Cancer Hospital, Zhengzhou

The First People's Hospital of Ping Ding Shan, Zhengzhou

455112

Anyang People's Hospital, Anyang

473001

Nanyang Central Hospital, Nanyang

510515

Nanfang Hospital, Southern Medical University, Guangzhou

518000

Shenzhen Nanshan People's Hospital, Shenzhen

524045

Central People's Hospital of Zhanjiang, Zhanjiang

530005

The Second Affiliated Hospital of Guangxi Medical University, Nanning

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

570102

The First Affiliated Hospital of Hainan Medical University, Haikou

650033

Kunming Medical University Second Affiliated Hospital, Kunming

710000

Xijing Hospital, Xi'an

710018

Xi'an No.3 Hospital, Xi'an

710061

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

730000

The First Hospital of Lanzhou University, Lanzhou

810000

Qinghai University Affiliated Hospital, Xining

830000

People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

071000

Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding

067000

Affiliated Hospital of ChengDe Medical University, Chengde

050023

The First Hospital of Hebei Medical University, Shijiazhuang

063000

North China University of science and technology, Tangshan

046000

Heping Hospital affiliated to Changzhi Medical College, Changzhi

030032

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY